Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 15;182(6):1348–1358. doi: 10.1111/bjd.18851

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Proportion of patients achieving resolution of patient‐reported outcomes for the ixekizumab (IXE, N = 520) and guselkumab (GUS, N = 507) groups. Data are percentage (with 95% confidence interval). Proportion of patients achieving a score of (a) 0 or 1 for the Patient's Global Assessment (PatGA) and static Physician's Global Assessment (sPGA); (b) 0 or 1 for the Dermatology Life Quality Index (DLQI); and (c) 0 for the itch numeric rating scale (NRS). In (c), only patients with baseline Itch NRS score > 0 were included (IXE n = 515 and GUS n = 495). (d) The proportion of patients achieving DLQI of 0 or 1 based on week 2 75% improvement in Psoriasis Area and Severity Index (PASI 75) is shown after treatment groups were pooled. Nonresponder imputation was used for missing data. The 95% confidence intervals were constructed using the asymptotic method, without continuity correction (i.e. normal approximation to the binomial distribution).